BACKGROUND: Evidence suggests that Epstein-Barr virus (EBV) plays a role in triggering or perpetuating disease activity in multiple sclerosis (MS). METHODS: We investigated 100 subjects (50 clinically isolated syndrome [CIS], 25 relapsing-remitting [RR] MS, 25 primary progressive [PP] MS) for 1) evidence of EBV reactivation and 2) disease activity as indicated by serial gadolinium (Gd)-enhanced MRIs over a 5-year period. EBV DNA in blood was quantified by real-time quantitative PCR and EBV serology for anti-Epstein-Barr virus nuclear antigen 1 (EBNA-1) immunoglobulin G (IgG), anti-viral capsid antigen (VCA) IgG, and anti-EBV IgM. Data were analyzed using repeated measures analysis, analysis of variance, and logistic regression analysis. RESULTS: All subjects had serologic evidence of previous EBV infection, but no lytic reactivation was detected. Significant differences in EBNA-1 IgG titers were found between subgroups, highest in the RRMS cohort compared with PPMS (p < 0.001) and CIS (p < 0.001). Gd-enhancing lesions on MRI correlated with EBNA-1 IgG (r = 0.33, p < 0.001) and EBNA-1:VCA IgG ratio (r = 0.36, p < 0.001). EBNA-1 IgG also correlated with change in T2 lesion volume (r = 0.27, p = 0.044) and Expanded Disability Status Scale score (r = 0.3, p = 0.035). CONCLUSIONS: The correlation between elevated Epstein-Barr virus nuclear antigen 1 (EBNA-1) immunoglobulin G (IgG) and gadolinium-enhancing lesions suggests an association between Epstein-Barr virus (EBV) infection and multiple sclerosis (MS) disease activity. The heightened immune response to EBV in MS is specifically related to EBNA-1 IgG, a marker of the latent phase of the virus. The lack of association between acute viral reactivation in the peripheral blood and Gd(+) lesions suggests a limited role of the former in driving disease activity.
BACKGROUND: Evidence suggests that Epstein-Barr virus (EBV) plays a role in triggering or perpetuating disease activity in multiple sclerosis (MS). METHODS: We investigated 100 subjects (50 clinically isolated syndrome [CIS], 25 relapsing-remitting [RR] MS, 25 primary progressive [PP] MS) for 1) evidence of EBV reactivation and 2) disease activity as indicated by serial gadolinium (Gd)-enhanced MRIs over a 5-year period. EBV DNA in blood was quantified by real-time quantitative PCR and EBV serology for anti-Epstein-Barr virus nuclear antigen 1 (EBNA-1) immunoglobulin G (IgG), anti-viral capsid antigen (VCA) IgG, and anti-EBV IgM. Data were analyzed using repeated measures analysis, analysis of variance, and logistic regression analysis. RESULTS: All subjects had serologic evidence of previous EBV infection, but no lytic reactivation was detected. Significant differences in EBNA-1 IgG titers were found between subgroups, highest in the RRMS cohort compared with PPMS (p < 0.001) and CIS (p < 0.001). Gd-enhancing lesions on MRI correlated with EBNA-1 IgG (r = 0.33, p < 0.001) and EBNA-1:VCA IgG ratio (r = 0.36, p < 0.001). EBNA-1 IgG also correlated with change in T2 lesion volume (r = 0.27, p = 0.044) and Expanded Disability Status Scale score (r = 0.3, p = 0.035). CONCLUSIONS: The correlation between elevated Epstein-Barr virus nuclear antigen 1 (EBNA-1) immunoglobulin G (IgG) and gadolinium-enhancing lesions suggests an association between Epstein-Barr virus (EBV) infection and multiple sclerosis (MS) disease activity. The heightened immune response to EBV in MS is specifically related to EBNA-1 IgG, a marker of the latent phase of the virus. The lack of association between acute viral reactivation in the peripheral blood and Gd(+) lesions suggests a limited role of the former in driving disease activity.
Authors: N C Silver; C D Good; G J Barker; D G MacManus; A J Thompson; I F Moseley; W I McDonald; D H Miller Journal: Brain Date: 1997-07 Impact factor: 13.501
Authors: J H van Waesberghe; J A Castelijns; W Roser; N Silver; T Yousry; G J Lycklama à Nijeholt; H J Adèr; B M Uitdehaag; E W Radue; C H Polman; L Kappos; D H Miller; F Barkhof Journal: AJNR Am J Neuroradiol Date: 1997-08 Impact factor: 3.825
Authors: M Filippi; M Rovaris; R Capra; C Gasperini; T A Yousry; M P Sormani; F Prandini; M A Horsfield; V Martinelli; S Bastianello; I Kühne; C Pozzilli; G Comi Journal: Brain Date: 1998-10 Impact factor: 13.501
Authors: A C van Sechel; J J Bajramovic; M J van Stipdonk; C Persoon-Deen; S B Geutskens; J M van Noort Journal: J Immunol Date: 1999-01-01 Impact factor: 5.422
Authors: M Andersson; J Alvarez-Cermeño; G Bernardi; I Cogato; P Fredman; J Frederiksen; S Fredrikson; P Gallo; L M Grimaldi; M Grønning Journal: J Neurol Neurosurg Psychiatry Date: 1994-08 Impact factor: 10.154
Authors: Adam E Handel; Alexander J Williamson; Giulio Disanto; Lahiru Handunnetthi; Gavin Giovannoni; Sreeram V Ramagopalan Journal: PLoS One Date: 2010-09-01 Impact factor: 3.240